Back to Browse Journals » Research and Reports in Urology » Volume 3

Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer

Authors Solanki AA, Liauw SL

Published Date June 2011 Volume 2011:3 Pages 95—104

DOI http://dx.doi.org/10.2147/RRU.S14245

Published 15 June 2011

Abhishek A Solanki, Stanley L Liauw
Department of Radiation and Cellular Oncology, University of Chicago Medical Center, Chicago, IL, USA

Abstract: Brachytherapy and external beam radiotherapy are effective and commonly used treatment modalities in men with localized prostate cancer. In this review, we explore the role of radiation therapy in the curative management of prostate cancer, including the use of conformal therapeutic techniques to allow for the escalation of radiation doses to tumor, along with the use of combined radiation and hormonal therapy to enhance disease outcomes in men with aggressive disease. We also review the possible anticancer role of HMG-CoA reductase inhibiting agents (statins) in men with prostate cancer. Laboratory evidence suggests that statins may have antineoplastic effects when used alone and may sensitize cells to radiation therapy when given in combination. We explore the biologic basis for an anticancer effect and the clinical evidence suggesting statins may aid in improving outcomes with radiation therapy for localized prostate cancer.

Keywords:
HMG-CoA reductase inhibitors, statins, radiotherapy, prostate cancer

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Readers of this article also read:

Ultrasound-targeted stromal cell-derived factor-1-loaded microbubble destruction promotes mesenchymal stem cell homing to kidneys in diabetic nephropathy rats

Wu S, Li L, Wang G, Shen W, Xu Y, Liu Z, Zhuo Z, Xia H, Gao Y, Tan K

International Journal of Nanomedicine 2014, 9:5639-5651

Published Date: 3 December 2014

Posttraumatic stress symptoms, dissociation, and alexithymia in an Italian sample of flood victims

Craparo G, Gori A, Mazzola E, Petruccelli I, Pellerone M, Rotondo G

Neuropsychiatric Disease and Treatment 2014, 10:2281-2284

Published Date: 28 November 2014

A novel nonsense mutation of the KAL1 gene (p.Trp204*) in Kallmann syndrome

El Husny AS, Raiol-Moraes M, Fernandes-Caldato MC, Ribeiro-dos-Santos Â

The Application of Clinical Genetics 2014, 7:177-182

Published Date: 30 September 2014

A cross-sectional study on perception of stigma by Chinese schizophrenia patients [Expression of concern]

Ren ZB, Wang HQ, Feng B, Gu CY, Ma YC, Chen H, Li BL, Liu LY

Neuropsychiatric Disease and Treatment 2014, 10:1333-1334

Published Date: 18 July 2014

Proposed criteria for schizophrenia remission

AlAqeel B

Neuropsychiatric Disease and Treatment 2014, 10:619-623

Published Date: 16 April 2014

Potential use of custirsen to treat prostate cancer

Higano CS

OncoTargets and Therapy 2013, 6:785-797

Published Date: 25 June 2013

Neurotransmitter testing of the urine: a comprehensive analysis

Marty Hinz, Alvin Stein, George Trachte, et al

Research and Reports in Urology 2010, 2:177-183

Published Date: 7 October 2010

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab

Daanish Hoda, George R Simon, Christopher R Garrett

Therapeutics and Clinical Risk Management 2008, 4:1221-1227

Published Date: 1 September 2008